Objective Previous studies have shown that 5% to 15% of healthy people do not show a protective antibody response following hepatitis B vaccination. The study was done to determine the protective efficacy of vaccination in healthy young adults 1 to 4 years after the three dose vaccination series and to study the effect of a booster dose on nonresponders and hypo-responders.
Introduction
The discovery of the aetiologic agent of hepatitis B (HB) and the development of safe and effective vaccines is one of the remarkable achievements of the 20th century. HB is transmitted by percutaneous or permucosal expo sure to infectious body fluids, by sexual contact with an infected person and perinatally from an infected mother to her infant. The consequences of acute hepatitis B virus (HBV) infection-are variable. Newborn babies are gener ally asymptomatic and the typical illness is seen in only 5 to 15% of children 1 to 5 years of age (1) . Older children and adults are symptomatic in 33 to 50% of infections. Fulminant hepatitis occurs in 1 to 2% of people with acute disease, which has a case fatality rate of 63 to 93%.
Chronic HBV infection is defined as the presence of HBsAg in serum for at least 6 months. The risk of develop ing chronic infection is highest for infants (about 90%) infected in the perinatal period, compared to 6 to 10% of acutely infected adults (2) . 15% of adolescents and young adults with chronic HBV infection are at substantially in creased risk of developing chronic liver disease, including cirrhosis of the liver and hepatocellular carcinoma.
In Sri Lanka epidemiological surveys of the commu nity and in blood donors show that the prevalence of chronic HBV infection is low, ranging between 0.7 and 2.5% (3). A survey in 1996 showed a prevalence of 0.15% among all categories of health care workers (3/2000) and 0.5% in medical officers (1/206) (4) . A study of 456 medical students before exposure to clinical work showed a prevalence of 0.44% (5).
Vaccination of individuals at risk of exposure to HBV has been the main method of controlling the morbidity and mortality associated with HBV. The recommended schedule of vaccination of healthy subjects consists of three doses at 0, 1 and 6 months. The protective efficacy of HB vaccination is directly related to the development of anti-HBs antibodies. Those who develop anti-HBs titres of >10 mlU/ml after a primary vaccination series are protected against clinical illness and chronic infection (6) . Studies of the antibody response to currently licensed plasma derived hepatitis B vaccines and hepatitis B vaccines prepared by recombinant technology have shown that between 5 to 10% or more of healthy people do not show an anti-HBs antibody response to the surface antigen component (HbsAg) of these preparations (nonresponders), or respond poorly (hypo-responders) (7), conditions that are defined as showing less than 10 mlU/ ml and 10 to 100 mlU/ml of anti-HBs respectively against an international antibody standard. Non-responders remain susceptible to infection with HBV.
The recommended series of three intramuscular doses of HB vaccine induces a protective antibody response in over 90% of healthy adults below 40 years of age. By the age of 60 years only 75% of people vaccinated develop protective levels of anti-HBs (8) . Host factors such as smoking, obesity, immunosuppression, past HBV infec tion, of immune deficiency disorders and chronic illnesses adversely affect the antibody response.
Methods

Study group
The study was conducted at the Faculty of Medi cine, Colombo from January to June 2000. The study popu-Papers lation comprised 258 medical students who had been vac cinated with three doses of the recombinant vaccine intra muscularly to the deltoid region at 0, 1 and 6 months.
Study design
Blood samples from the study group were tested for anti-HBs titre using a quantitative enzyme linked immunosorbent assay (ELISA) by Abbot-Murex. Data on factors known to affect seroconversion were obtained using a self-administered questionnaire. The data included sex, age, body weight and height, duration after vaccina tion, presence of a chronic disease such as diabetes and other immune deficiency states.
The risk of infection with HBV was also assessed from a history of needle pricks, family or close contact with a chronic carrier of HBV and sexual contact.
In the second phase of the study, participants who did not have protective antibody levels (non-responders, anti-HBs less than 10 mlU/ml) and hypo-responders (antiHBs less than 100 mlU/ml) were given a booster dose of the vaccine and retested after one month for seroconversion or a rise in the anti-HBs antibody titre. Participants who did not seroconvert after this were investigated further by an interview to probe their past medical history and by testing for serological evidence (anti-HB core antibody) of past HBV infection.
titres in relation to duration of vaccination. In our study there was no significant association between the anti-HBs titre and duration after vaccination which varied from 12 to 40 months. Sex and body mass index were not significantly associated with seroconversion. Type of vaccine, dose and route of vaccination were not significant variables.
In the study population 64 gave a history of acciden tal needle pricks, 2 had close contact with a chronic hepa titis B patient, and 8 have had homosexual or heterosexual intercourse. Hence 28.6% had a potential risk factor for acquiring HBV infection.
Among the 26 non-responders (anti-HBs <10 mil)/ ml), 22 volunteered for retesting after a booster dose of HB vaccine. Among the 103 hypo-responders 12 who had antiHBs titres of 10-100 mlU/ml were retested after a booster dose. All hypo-responders developed anti-HBs titres over 100 mlU/ml. Among the 22 initial non-responders, 3 (13.6%) continued to be negative for anti-HBs antibodies, but did not have any identifiable chronic illness and tested nega tive for anti-HB core (HBc) antibodies indicating absence of past HBV infection.
Table 1. Number of student volunteers from each batch and duration after vaccination
Results
The participants were from 13 districts of the island, and the percentages were, Colombo 58.2, Gampaha 15. Table 1 . 90.3% (223/258) showed a protective antibody response (anti-HBs >10 mlU/ml) fol lowing vaccination. 9.5% were non-responders. The ma jority (54%) showed a good antibody response (> 100 mlU/ ml) against HBV infection. 
Papers Discussion
The minimum protective level of anti-HBs following immunisation has been set in protective efficacy studies at 10 mlU/ml. The titre required for protection against par ticular routes of infection and the size of the inoculum may vary. For example, a follow up study of vaccinated homo sexual men reported an overall incidence of HBV infection of 2.9 per 100 person years, with nearly 75% occurring in people with an anti-HBs titre less 10 mlU/ml at the time of infection, and in only a few with anti-HBs titres over 50 mlU/ml (10) . A much lower asymptomatic HBV infection rate of 0.8 per 100 person years was observed after immunisation of health care workers in nephrology units who had antibody titres less than 50 mlU/ml (11).
Vaccine induced anti-HBs titres are highest one month after booster vaccination, but decline rapidly during the next 12 months and thereafter more slowly (6).
Providing booster vaccination to all vaccinated sub jects at regular intervals without determination of anti-HBs is not supported by evidence (15, 16) . Testing of the anti body level one month after the last dose of vaccination is recommended to identify non-responders and hyporesponders (16, 17) . Numerous studies indicate that adminis tration of four, five, six or more doses of the vaccine in non-responders or hypo-responders results in production of protectice levels of anti-HBs in about 50% (12, 13, 14, 15) . In our study a booster dose of the vaccine resulted in 86% of non-responders developing protective anti-HBs levels.
The European Consensus Group on hepatitis B immunisation recommends the following for health care workers and others at occupational risk who do not de velop protective anti-HBs titres after the initial vaccina tion series (16) : screen for markers of present or past HBV infection (HbsAg, anti-HBc); administer an additional booster dose of the vaccine, repeat anti-HBs measurement; consider passive immunisation with HB immunoglobulin following exposure.
The US Public Health Service Guidelines for the man agement of occupational exposures to HBV recommends that people who do not respond to the primary vaccine series be given a second 3-dose series as there is a 30 to 50% chance of responding to the latter (17) .
